PARIS and NEW YORK, April 07, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, has released an update on how the current COVID-19 health crisis will impact its clinical research activities. Together with their partners, including suppliers, service providers, and clinical research organizations, Quantum Genomics is taking all necessary measures to maintain its clinical development activities while ensuring that the safety of its staff and enrolled patients remains its top priority Continue reading →

The reduction in cardiovascular (CV) events seen in the REDUCE-IT trial with icosapent ethyl (Vascepa, Amarin), a high-strength formulation of purified eicosapentaenoic acid (EPA), were directly related to on-treatment serum levels of EPA, and not to a decrease in triglyceride levels as had originally been anticipated, a new analysis confirms. "The benefits in the REDUCE-IT cannot be explained by the degree of changes to triglycerides or other biomarkers such as LDL cholesterol or CRP [C-reactive protein] Continue reading →

Karnataka registered its first death of a frontline health worker helping in COVID-19 treatment. Saravana M (35), a a junior health assistant who was part of the COVID screening team at Hebbuni checkpost in Mulbagal, Kolar district, died while on duty Continue reading →

Many finns stand now for too long the heart symptoms. This shows heart hospitals, and doctors are concerned about the phenomenon. Continue reading →

Global Cardiac Marker Analyzer Market: Overview The global cardiac marker analyzer market is anticipated to rise at a noteworthy pace in the years ahead. The high-value applications of cardiac marker analyzer accounts for the high growth prospects of the cardiac marker analyzer market Continue reading →

Caution in prescribing off-label medicines, and deferring coronary angiography in stable patients with COVID-19 and suspected myocardial infarction, are two of the key recommendations issued in the consensus statement on cardiovascular disease (CVD) and COVID-19. The Heart Foundation has summarised the advice to cardiac health services in a consensus statement endorsed by the Heart Foundation, Cardiac Society of Australia and New Zealand (CSANZ), and the High Blood Pressure Research Council of Australia. This statement is the first of its kind to be released in Australia and summarises the available data on COVID-19 and cardiovascular disease, said co-author, Heart Foundation Chief Medical Adviser, cardiologist Professor Garry Jennings. Continue reading →

Executive Summary Introduction/Background By itemizing charges for each individual service and procedure performed during an episode of care, Medicare fee-for-service (FFS) encourages greater utilization of provider services and, thus, higher healthcare costs. To facilitate phasing out FFS for hospitals, the Social Security Amendments of 1983 established the Prospective Payment System (PPS) for Medicare.[1] The goal of the PPS was to alter hospital behavior under the FFS structure by incentivizing more cost-efficient care management. This law consolidated charges for care received in a hospital, paid by Part A, into one lump sum through the Diagnosis-Related Group (DRG) classification systema departure from the separate, itemized charges under FFS Continue reading →